{
  "variants": [
    {
      "variant": "A30P",
      "description": "PD-associated mutant of α-synuclein",
      "functional_evidence": "The paper states that A30P is a Parkinson's disease-associated mutant, but it does not explicitly compare its PLD2 inhibition potency to wild-type α-synuclein. However, the study highlights that A53T is more potent than wild-type, and A30P is a known PD-related variant.",
      "acmg_steps": [
        {
          "step": "Disease Mechanism Defined",
          "outcome": "Yes (PD is linked to α-synuclein's role in PLD2 inhibition)."
        },
        {
          "step": "Assay Applicability",
          "outcome": "Yes (PLD2 inhibition is relevant to the disease mechanism)."
        },
        {
          "step": "Assay Validity",
          "outcome": "Yes (the study compares multiple variants, including known mutants, to assess inhibition potency)."
        },
        {
          "step": "Statistical Analysis",
          "outcome": "No direct statistical tests mentioned, but the comparison between variants (e.g., A53T vs. wild-type) provides qualitative evidence."
        }
      ],
      "strength": "PS3_supporting"
    },
    {
      "variant": "A53T",
      "description": "PD-associated mutant of α-synuclein",
      "functional_evidence": "The paper explicitly states that A53T is a more potent inhibitor of PLD2 than wild-type α-synuclein, indicating stronger functional impairment.",
      "acmg_steps": [
        {
          "step": "Disease Mechanism Defined",
          "outcome": "Yes (PD is linked to α-synuclein's role in PLD2 inhibition)."
        },
        {
          "step": "Assay Applicability",
          "outcome": "Yes (PLD2 inhibition is relevant to the disease mechanism)."
        },
        {
          "step": "Assay Validity",
          "outcome": "Yes (the study directly compares A53T to wild-type and other mutants)."
        },
        {
          "step": "Statistical Analysis",
          "outcome": "No direct statistical tests mentioned, but the comparison between variants provides qualitative evidence."
        }
      ],
      "strength": "PS3_very_strong"
    },
    {
      "variant": "Exon 4 Deletion (residues 56–102)",
      "description": "Deletion of exon 4 in α-synuclein",
      "functional_evidence": "The paper states that deletion of exon 4 reduces PLD2 inhibition, indicating a structural defect in the protein's inhibitory function.",
      "acmg_steps": [
        {
          "step": "Disease Mechanism Defined",
          "outcome": "Yes (PLD2 inhibition is relevant to the disease mechanism)."
        },
        {
          "step": "Assay Applicability",
          "outcome": "Yes (PLD2 inhibition is relevant to the disease mechanism)."
        },
        {
          "step": "Assay Validity",
          "outcome": "Yes (the study directly tests the effect of this deletion on inhibition)."
        },
        {
          "step": "Statistical Analysis",
          "outcome": "No direct statistical tests mentioned, but the qualitative effect of the deletion provides evidence."
        }
      ],
      "strength": "PS3_very_strong"
    },
    {
      "variant": "Exon 6 Deletion (residues 130–140)",
      "description": "Deletion of exon 6 in α-synuclein",
      "functional_evidence": "The paper states that deletion of exon 6 completely abolishes PLD2 inhibition, indicating a critical structural role in the protein's function.",
      "acmg_steps": [
        {
          "step": "Disease Mechanism Defined",
          "outcome": "Yes (PLD2 inhibition is relevant to the disease mechanism)."
        },
        {
          "step": "Assay Applicability",
          "outcome": "Yes (PLD2 inhibition is relevant to the disease mechanism)."
        },
        {
          "step": "Assay Validity",
          "outcome": "Yes (the study directly tests the effect of this deletion on inhibition)."
        },
        {
          "step": "Statistical Analysis",
          "outcome": "No direct statistical tests mentioned, but the qualitative effect of the deletion provides evidence."
        }
      ],
      "strength": "PS3_very_strong"
    },
    {
      "variant": "Phosphorylation at Serine 129",
      "description": "Phosphorylation of α-synuclein at serine 129",
      "functional_evidence": "The paper states that phosphorylation at this site blocks PLD2 inhibition, indicating a regulatory role in the protein's function.",
      "acmg_steps": [
        {
          "step": "Disease Mechanism Defined",
          "outcome": "Yes (PLD2 inhibition is relevant to the disease mechanism)."
        },
        {
          "step": "Assay Applicability",
          "outcome": "Yes (PLD2 inhibition is relevant to the disease mechanism)."
        },
        {
          "step": "Assay Validity",
          "outcome": "Yes (the study directly tests the effect of this modification on inhibition)."
        },
        {
          "step": "Statistical Analysis",
          "outcome": "No direct statistical tests mentioned, but the qualitative effect of the modification provides evidence."
        }
      ],
      "strength": "PS3_very_strong"
    }
  ]
}